Jazz consensus expectations too low, says Lazard Capital Lazard Capital believes consensus expectations for Jazz Pharmaceuticals are too low following the company's Xyrem price increase last week. The firm keeps a Buy rating on the stock with an $87 price target.
News For JAZZ From The Last 14 Days
Check below for free stories on JAZZ the last two weeks.
Allergan merger deal not imminent, CNBC's Faber reports An acquisition by Allergan (AGN) is not imminent, CNBC's David Faber reports. Salix (SLXP) and Jazz Pharmaceuticals (JAZZ) are said to be potential targets of the company, Faber adds. Valeant (VRX) could announce over the next few days that it has enough votes to call for a special meeting, the reported said.